– USA, CA – DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the additions of Lisa Bowers and Dr. Mittie Doyle (M.D., FACR) to its board of directors.
“Lisa and Mittie are excellent additions to the DICE team with extensive biopharmaceutical industry experience and expertise in their respective fields,” said CEO, Dr. Kevin Judice. “We are pleased to welcome them to DICE during this important time in the Company’s growth and evolution. We would also like to thank Stephen for his many contributions during his time on our board, including during the early stages of the Company’s formation.”
Concurrently, Dr. Stephen Zachary will be stepping down from the board, and Mary Riley is appointed as general counsel.
About Lisa Bowers
Ms. Bowers is the CCO of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company founded to address a critical unmet need, the lack of therapeutic development in pediatric cancer. Before joining Day One, Lisa served as CEO and founder of Rhia Ventures, a social venture investment organization focused on reproductive health. She was also COO of the Tara Health Foundation and had an extensive career at Genentech/Roche, where she held P&L accountability for Genentech’s cystic fibrosis business and was the head of the North American supply chain region, accountable for more than $20 billion of medicine across the U.S. and Canada. Before these roles, Ms. Bowers led Genentech’s patient access services and the company’s strategic marketing function for managed care organizations. Ms. Bowers has been a board observer for Cadence Health and is a member of the board for Planned Parenthood Mar Monte.
She received a Master of Health Services Administration from the University of Michigan School of Public Health and a B.A. from Yale University.
About Dr. Mittie Doyle
Dr. Doyle is a proven research physician who has held numerous leadership roles in clinical development. She currently serves as CMO of Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines. Before joining Aro, Dr. Doyle served as VP, global therapeutic area head, immunology at CSL Behring. Before her time at CSL, Dr. Doyle held senior-level roles at Shire Pharmaceuticals, Flexion Therapeutics, and Alexion Pharmaceuticals. During her career, she has led clinical development across a broad range of immune-mediated and orphan diseases and led teams with responsibilities for the design and execution of first-in-human through Phase 2 and 3 trials, resulting in several global regulatory approvals.
Dr. Doyle received an M.D. from Yale Medical School and completed her postdoctoral training at Harvard Medical School including a residency in internal medicine at Massachusetts General Hospital and a clinical/research fellowship in rheumatology and immunology at Brigham Women’s Hospital. She received a B.A. from Princeton University.
About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, to achieve comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
For more information: https://www.dicetherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
